1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsExploratory Cancer Immunology Projects and Technologies (ExCITe) is sponsored by National Cancer Institute (NCI)/NIH. This Notice of Special Interest (NOSI) funds exploratory projects in early discovery immunology, ideal for researchers investigating underexplored mechanisms of immune regulation, metastasis, or immune evasion.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Notice of Special Interest (NOSI): Exploratory Cancer Immunology Projects and Technologies (ExCITe) | Research Funding National Institutes of Health Notice of Special Interest (NOSI): Exploratory Cancer Immunology Projects and Technologies (ExCITe) Through this Notice of Special Interest (NOSI) on Exploratory Cancer Immunology Projects and Technologies (ExCITe), the National Cancer Institute intends to encourage R21 applications proposing innovative high-risk/high-reward research projects, that test novel hypotheses or develop novel technologies, to advance our understanding of cancer immunology.
Research projects should focus on fundamental areas of cancer immunology, including innate and adaptive immune responses, tumor-immune ecosystems and their dynamic interactions, the immune response to metastases, systemic immune networks, immunosurveillance, tumor immune evasion, or immunomodulation. Projects should be distinct in scope and focus from those supported through the traditional R01 mechanism.
ExCITe studies may involve considerable risk but have the potential to lead to research breakthroughs or the development of novel techniques, agents, methodologies, models, or applications that could have a major impact in cancer immunology and cancer immunotherapy research.
R21 applications submitted through the ExCITe NOSI should propose innovative high-risk/high-reward research projects, that test novel hypotheses or develop novel technologies, to advance our understanding of cancer immunology. Applicants should propose research studies to address fundamental aspects in the field of tumor immunology and/or innovative ways to enhance anti-cancer immunity.
Innovative approaches that target both primary tumor and metastases are encouraged. Establishing new or improved in vivo/in vitro models to study the dynamics of tumor-immune ecosystems are also encouraged. This notice applies to due dates on or after February 16, 2024 and subsequent receipt dates through November 17, 2026.
Medical - Clinical Science
According to the current listing, eligibility includes: U. S. -based researchers at NIH-eligible institutions. Proposals must be distinct from standard funding opportunity announcements. Confirm the full requirements in the official notice before applying.
Applications for Exploratory Cancer Immunology Projects and Technologies (ExCITe) are due November 17, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Exploratory Cancer Immunology Projects and Technologies (ExCITe) is funded by National Cancer Institute (NCI)/NIH. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
PAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read articlePA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read article